Medicare spending analysis for Rheumatology providers
Rheumatology accounts for $16.3B in Medicare payments across 46.2K providers.
The specialty's average markup of 2.7x is below the overall Medicare average of 3.77x.
AI-generated analysis based on Medicare payment data.
Providers in this specialty flagged by the ML v2 fraud detection model
| Year | Payments | Services | Providers | YoY Change |
|---|---|---|---|---|
| 2014 | $1.1B | 51.8M | 4.3K | — |
| 2015 | $1.2B | 59.3M | 4.4K | +10.5% |
| 2016 | $1.4B | 70.1M | 4.5K | +13.9% |
| 2017 | $1.6B | 78.0M | 4.5K | +9.5% |
| 2018 | $1.7B | 87.5M | 4.6K | +9.9% |
| 2019 | $1.8B | 101.0M | 4.7K | +7.7% |
| 2020 | $1.9B | 110.3M | 4.7K | +1.1% |
| 2021 | $1.9B | 121.0M | 4.8K | +3.3% |
| 2022 | $1.8B | 133.3M | 4.9K | -6.2% |
| 2023 | $1.8B | 146.1M | 4.9K | +0.4% |
| # | Provider | State | Payments | Services | Avg/Service |
|---|---|---|---|---|---|
| 1 | Craig Carson | OK | $9.7M | 726.1K | $13.31 |
| 2 | Nehal Gandhi | PA | $8.0M | 902.2K | $8.89 |
| 3 | Joy Schechtman | AZ | $7.8M | 757.8K | $10.24 |
| 4 | Elizabeth Clayton | MD | $7.1M | 608.8K | $11.60 |
| 5 | Barry Eibschutz | CA | $6.6M | 472.3K | $14.06 |
| 6 | Aaron Broadwell | LA | $6.4M | 522.1K | $12.27 |
| 7 | Shariar Cohen-Gadol | CA | $6.2M | 529.2K | $11.66 |
| 8 | Vipul Joshi | FL | $5.6M | 629.4K | $8.83 |
| 9 | Nehad Soloman | AZ | $5.1M | 483.5K | $10.48 |
| 10 | Michael Joseph | MO | $5.1M | 406.1K | $12.47 |
| 11 | Larry Broadwell | LA | $5.0M | 385.2K | $12.92 |
| 12 | Aymen Kenawy | FL | $5.0M | 288.1K | $17.26 |
| 13 | Richard Houk | AR | $4.9M | 356.0K | $13.68 |
| 14 | Rachel Chase | KY | $4.8M | 412.9K | $11.70 |
| 15 | Arash Horizon | CA | $4.8M | 428.9K | $11.23 |
| 16 | Melvin Churchill | NE | $4.8M | 548.1K | $8.79 |
| 17 | Vinicius Costa Diniz Domingues | FL | $4.6M | 1.0M | $4.50 |
| 18 | Marc Hirsh | FL | $4.6M | 425.0K | $10.73 |
| 19 | David Carleton | VA | $4.3M | 733.7K | $5.90 |
| 20 | Richard Haddad | NJ | $4.3M | 541.7K | $7.91 |
| 21 | Phong Nguyen | VA | $4.2M | 468.8K | $8.99 |
| 22 | Steven Golombek | NJ | $4.2M | 419.3K | $9.98 |
| 23 | Ana Kumar | OK | $4.1M | 292.3K | $14.07 |
| 24 | Daniel Watrous | CA | $4.0M | 229.6K | $17.30 |
| 25 | Raza Hashmi | TN | $3.9M | 559.8K | $7.00 |
| Code | Description | Payments | Services | Avg/Service |
|---|---|---|---|---|
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | $376.3M | 11.3M | $33.38 |
| J0897 | Injection, denosumab, 1 mg | $219.1M | 12.0M | $18.26 |
| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | $192.8M | 49.6M | $3.89 |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | $178.4M | 17.2M | $10.40 |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | $166.0M | 1.9M | $89.17 |
| J3262 | Injection, tocilizumab, 1 mg | $129.0M | 27.9M | $4.63 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | $104.9M | 4.1M | $25.87 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | $75.1M | 9.5M | $7.88 |
| J9312 | Injection, rituximab, 10 mg | $61.7M | 996.6K | $61.95 |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | $38.1M | 379.1K | $100.54 |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | $29.5M | 471.3K | $62.60 |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | $26.7M | 211.1K | $126.72 |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | $21.3M | 180.6K | $118.00 |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | $19.3M | 334.3K | $57.73 |
| Q5104 | Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | $12.1M | 409.4K | $29.46 |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | $11.3M | 71.9K | $157.26 |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | $10.2M | 207.0K | $49.08 |
| J3245 | Injection, tildrakizumab, 1 mg | $8.6M | 78.9K | $109.10 |
| 20610 | Aspiration and/or injection of fluid from large joint | $8.1M | 154.2K | $52.41 |
| J0490 | Injection, belimumab, 10 mg | $7.6M | 210.0K | $36.15 |
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.